^
    3d
    GO39932: A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer (clinicaltrials.gov)
    P1, N=181, Active, not recruiting, Genentech, Inc. | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • triptorelin • goserelin acetate • giredestrant (RG6171)
    3d
    RIBOLARIS: Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer (clinicaltrials.gov)
    P2, N=1100, Active, not recruiting, SOLTI Breast Cancer Research Group | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint® • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
    |
    docetaxel • doxorubicin hydrochloride • cyclophosphamide • Kisqali (ribociclib)
    5d
    Single-cell transcriptomics reveals immune landscape dynamics in metastatic hormone receptor-positive breast cancer treated with abemaciclib and endocrine therapy. (PubMed, Clin Cancer Res)
    Our data reveal heterogeneous lymphoid and myeloid subpopulations in advanced and metastatic breast tumors that are associated with late progression on abemaciclib and ET and overall survival in breast cancer patients.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CDK4 (Cyclin-dependent kinase 4) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • TREM2 (Triggering Receptor Expressed On Myeloid Cells 2)
    |
    ER positive • HR positive • HER-2 negative
    |
    Verzenio (abemaciclib)
    5d
    Body Mass Index and Outcomes in HR+/HER2- Metastatic Breast Cancer Treated with Palbociclib: Insights from a National Real-World Study. (PubMed, Cancers (Basel))
    While clinically informative, these results should not be interpreted as definitive evidence that body weight has no influence on palbociclib efficacy, given the methodological constraints of the analysis. BMI alone may be insufficient to capture the complex interplay between body composition and treatment outcomes, highlighting the need for more refined biomarkers of body composition in this setting.
    Journal • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Ibrance (palbociclib)
    5d
    Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study (clinicaltrials.gov)
    P2, N=2000, Recruiting, Fujian Cancer Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    tamoxifen • fulvestrant • letrozole • anastrozole • exemestane • AiRuiKang (dalpiciclib)
    5d
    Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC (clinicaltrials.gov)
    P2, N=14, Completed, Case Comprehensive Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Apr 2026 | Trial primary completion date: Dec 2025 --> Apr 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Verzenio (abemaciclib)
    5d
    EORTC 1745-ETF-BCG: Adjuvant Palbociclib in Elderly Patients With Breast Cancer (clinicaltrials.gov)
    P2, N=366, Active, not recruiting, European Organisation for Research and Treatment of Cancer - EORTC | Trial completion date: Sep 2032 --> Sep 2026 | Trial primary completion date: Jun 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • paclitaxel • docetaxel • doxorubicin hydrochloride • cyclophosphamide • epirubicin
    6d
    Emulation of the PALOMA-2 Trial (clinicaltrials.gov)
    P=N/A, N=6097, Completed, Brigham and Women's Hospital | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • letrozole
    6d
    UCLA B-13: Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer (clinicaltrials.gov)
    P1/2, N=18, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Apr 2027 --> Apr 2028 | Trial primary completion date: Apr 2026 --> Apr 2027 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HER-2 amplification
    |
    carboplatin • docetaxel • Perjeta (pertuzumab) • Kisqali (ribociclib) • fulvestrant • Tukysa (tucatinib) • Herzuma (trastuzumab-pkrb) • Trazimera (trastuzumab-qyyp)
    6d
    Efficacy, Safety, and Prognostic Factors of Dalpiciclib Combined with Endocrine Therapy After Progression on CDK4/6 Inhibitors in Patients with HR+/HER2- Advanced Breast Cancer: A Retrospective Study. (PubMed, Breast Cancer (Dove Med Press))
    Subgroups including those without liver metastases, with secondary endocrine resistance, and receiving sequential CDK4/6i therapy appear to derive greater benefit. These findings support dalpiciclib as a viable cross-line therapeutic option, warranting further prospective validation.
    Clinical • Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    AiRuiKang (dalpiciclib)
    7d
    NoLEEta: Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib (clinicaltrials.gov)
    P3, N=3902, Recruiting, UNICANCER
    Trial initiation date • Head-to-Head
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    Kisqali (ribociclib)
    7d
    EX-AI: Impact of Exercise on Quality of Life of EBC Patients on Treatment With Adjuvant AI With or Without CDK4/6 Inhibitors (clinicaltrials.gov)
    P=N/A, N=74, Not yet recruiting, Spanish Breast Cancer Research Group
    Trial initiation date • HEOR
    |
    HER-2 (Human epidermal growth factor receptor 2) • CDK4 (Cyclin-dependent kinase 4)
    |
    HER-2 negative